Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 9.00 NOK
Change Today +0.86 / 10.57%
Volume 42.9K
As of 10:25 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

nattopharma asa (NATTO) Snapshot

8.30 NOK
Previous Close
8.14 NOK
Day High
9.35 NOK
Day Low
8.30 NOK
52 Week High
04/15/15 - 16.60 NOK
52 Week Low
09/1/15 - 7.66 NOK
Market Cap
Average Volume 10 Days
-1.43 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NATTOPHARMA ASA (NATTO)

Related News

No related news articles were found.

nattopharma asa (NATTO) Related Businessweek News

No Related Businessweek News Found

nattopharma asa (NATTO) Details

NattoPharma ASA produces nutrition supplements. It offers MenaQ7 that provides natural vitamin K2 (Menaquinone-7) as a fermentation extract for use in dietary supplements, and functional and fortified foods. The company sells its products through retail pharmacies. NattoPharma ASA was founded in 2004 and is based in Høvik, Norway.

10 Employees
Last Reported Date: 05/6/15
Founded in 2004

nattopharma asa (NATTO) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 655.0K NOK
Chief Operating Officer
Total Annual Compensation: 515.0K NOK
Senior Vice President of Global Marketing
Total Annual Compensation: 1.8M NOK
Senior Vice President of Sales & Marketing - ...
Total Annual Compensation: 718.0K NOK
Senior Vice President of R&D and Regulatory A...
Total Annual Compensation: 500.0K NOK
Compensation as of Fiscal Year 2014.

nattopharma asa (NATTO) Key Developments

NattoPharma ASA Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months June 30, 2015

NattoPharma ASA announced unaudited consolidated earnings results for the second quarter and six months June 30, 2015. For the quarter, the company reported sales revenue of NOK 7,724,000 compared to NOK 5,691,000 a year ago. Loss before income tax was NOK 7,877,000 compared to NOK 7,854,000 a year ago. Loss after income tax was NOK 7,245,000 compared to NOK 7,448,000 a year ago. LBITDA was NOK 6.5 million compared to NOK 6.5 million a year ago. Operating loss was NOK 7,877 million compared to NOK 7,854 million a year ago. Loss per share was NOK 0.47 compared to NOK 0.60 a year ago. For the six months, the company reported sales revenue of NOK 14,509,000 compared to NOK 9,739,000 a year ago. LBITDA was NOK 10.7 million compared to NOK 9.7 million a year ago. Net earnings were NOK 11.6 million compared to NOK 12.4 million a year ago. Operating loss was NOK 13,057 million compared to NOK 12,399 million a year ago. Loss per share was NOK 0.78 compared to NOK 1.03 a year ago. Net cash flow from operating activities was NOK 19,456 million compared to NOK 17,082 million a year ago. Investments in property, plant & equipment were NOK 34 million compared to NOK 776 million a year ago.

NattoPharma ASA, Q2 2015 Earnings Call, Aug 26, 2015

NattoPharma ASA, Q2 2015 Earnings Call, Aug 26, 2015

Mercola Selects NattoPharma as Preferred Supplier Partner

Nattopharma announced that Mercola selected it as a preferred supplier partner. Not only has Mercola included NattoPharma's MenaQ7® Vitamin K2 as MK-7 as a featured ingredient in the Dr. Mercola Premium Products line, but the two companies have combined their resources to educate consumers about the clinically validated health benefits of Vitamin K2.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NATTO:NO 9.00 NOK +0.86

NATTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NATTO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NATTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATTOPHARMA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at